PT-141
Also known as: Bremelanotide, Vyleesi
PT-141, also known as bremelanotide, is a melanocortin receptor agonist used in an FDA-approved product for acquired generalized hypoactive sexual desire disorder in premenopausal women. Its mechanism is centrally mediated melanocortin signaling, not a peripheral anabolic or metabolic pathway.
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Obstetrics and gynecology · 2019 · PMID 31599840
FDA-approved as Vyleesi for HSDD in premenopausal women. Dose as-needed, ≥45 min before anticipated sexual activity. Max 1 dose per 24 hours, 8 doses per month.
No published cycle data available.
Not for daily use. Tolerance develops if used too often.
Contraindications
- • Uncontrolled hypertension
- • Cardiovascular disease
Common side effects
- • Nausea (most common)
- • Flushing
- • Injection site reactions
- • Headache
- • Transient blood pressure increase
Serious risks
- • Focal hyperpigmentation (rare, with repeated use)
- • Blood pressure elevation — avoid in uncontrolled HTN
Drug interactions
- • May reduce efficacy of oral medications for 1-2 hours (delayed gastric emptying)
Requires monitoring
- • Blood pressure at baseline and periodically
Pregnancy / breastfeeding
Contraindicated in pregnancy
Male
Used off-label for erectile dysfunction; not FDA-approved for this use
Female
FDA-approved (Vyleesi) for HSDD in premenopausal women only
- Not a PDE5 inhibitor — works on melanocortin receptors in CNS
- Effect is not immediate — typically 30-90 minutes
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.